Polyethlene glycol modifications of thymosin alpha-1

Details Polyethlene glycol modifications of thymosin alpha-1 Polyethlene glycol modifications of thymosin alpha-1

2006-11-11

2011-12-20

Gupta, Anish (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S021300, C530S324000, C530S399000

Reexamination Certificate

active

08080522

ABSTRACT:
Polyethylene glycol modifications of thymosin alpha 1 (T&agr; 1-PEGs), their preparation process, the medicine composition containing them, and their application in the medicine for preventing and treating diseases related with immune deficiency and hypoimmunity, including hepatitis B, hepatitis C, hepatoma, malignant melanoma, non-small cell lung cancer, SARS, and AIDS etc.

REFERENCES:
patent: 1532207 (2004-09-01), None
patent: 1690079 (2005-11-01), None
patent: WO 03037272 (2003-05-01), None
Huijuan et al. CN1690079. English translation of the Chinese Patent. Nov. 2005.
Keliang et al. CN1532207. English Translation of Chinese Patent. Sep. 2004.
Ou-Yang et al. “Co-Delivery of GM-CSF Gene Enhances the Immune Responses of Hepatitis C Viral Core Protein-Expressing DNA Vaccine: Role of Dendritic Cells.” J. of Med. Virol. vol. 66, pp. 320-328. 2002.
Encke et al. :“Development of a heterologous, multigenotype vaccine against hepatitis C virus infection” Europ. J. of Clin. Inves. vol. 37, pp. 396-406. 2007.
Abrignani et al. Perspectives for a vaccine against hepatitis C virus. J. of Hepatology. vol. 31, Supp. 1, pp. 259-263. 1999.
Houghton et al. Prospects for a Vaccine against the Hepatitis C virus. Nature, vol. 436, pp. 961-966. Aug. 2005.
Bain et al. Effects of HCV Viral Dynamics on Treatment Design: Lessons Learned from HIV. American Journal of Gastroenterology. vol. 96, No. 10, pp. 2818-2828. 2001.
Hunt, Richard. “Virology—Chapter Twenty Five, Corona Viruses, Colds and SARS.” Retrieved from the Internet <URL:http://pathmicro.med.sc.edu/virol/coronaviruses.htm>. Apr. 6, 2010. Retrieved Feb. 14, 2011.
Braun et al. “Setting the stage for bench-to-bedside movment of anti-HIV RNA inhibitors-gene therapy for AIDS in macaques” Frontiers in Bioscience, vol. 11, pp. 838-851, Jan. 2006.
Gait et al. “Progress in anti-HIV structure based drug design.” TIBTECH, vol. 13. pp. 430-438, Oct. 1995.
Holmes, Kathryn. “SARS coronavirus: a new challenge for prevention and therapy.” J. Clin. Invest. 111:1605-1609 (2003).

Affiliated with

Also associated with

Rating

Polyethlene glycol modifications of thymosin alpha-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Polyethlene glycol modifications of thymosin alpha-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polyethlene glycol modifications of thymosin alpha-1 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4313387